Thyrocare Technologies Limited reported a consolidated profit of ₹162.85 crore for the financial year ended March 31, 2026, reflecting a 79% increase year-on-year, at its 26th Annual General Meeting (AGM) held on June 30, 2026. Consolidated revenue grew by 21% to ₹829.04 crore, driven by the processing of over 210 million tests during the year. The Independent Auditors’ Reports on both Standalone and Consolidated Financial Statements contained no qualifications, reservations, or adverse remarks.

The meeting, held at the Corporate Office in Navi Mumbai, saw the participation of 66 shareholders holding 61.10% of the total paid-up equity share capital. Mr. Rahul Franklin Guha, Chairman, Managing Director and Chief Executive Officer, chaired the proceedings. Shareholders approved the adoption of the audited standalone and consolidated financial statements for the year ended March 31, 2026.

Financial and Operational Highlights

Thyrocare served 19.2 million patients across India during the year, with a network spanning over 5,400 pin codes and supported by more than 10,800 quarterly active franchisees. The Chairman noted that 96% of samples were processed through NABL accredited owned laboratories, with an average turnaround time of 3.4 hours from sample receipt.

Key Governance Approvals

Shareholders declared a final dividend of ₹7.00 per equity share and confirmed the payment of an interim dividend of ₹7.00 per equity share (pre-bonus issue), equivalent to ₹2.33 per equity share post bonus adjustment, on shares with a face value of ₹10 each. The AGM approved the re-appointment of Mr. Rahul Franklin Guha as Chairman, Managing Director and Chief Executive Officer effective May 04, 2027, along with his remuneration.

M/s. Price Waterhouse Chartered Accountants LLP was appointed as the Statutory Auditors for a first term of five consecutive years. Additionally, shareholders approved the appointment of Mr. Gaurav Verma and Mr. Uday Patel Kadam as Directors (Non-Executive and Non-Independent) of the company with effect from May 08, 2026.

MOA Amendment Details

The amendment to the Memorandum of Association included the substitution of the heading of Clause III(A) to "THE OBJECTS TO BE PURSUED BY THE COMPANY ARE" and the addition of Sub clause 1B under Clause III(A)(1). This new sub-clause authorizes the company to carry on the business of establishing, setting up, acquiring, operating, managing or administering diagnostic facilities, including clinical laboratories and research centres. It also permits the development of healthcare and diagnostic data-driven digital platforms.

Further changes included the substitution of the heading of Clause III(B) to "Matters which are necessary for furtherance of the objects specified in Clause III(A) are:" and the deletion of the header of Clause III(C) regarding "Other Objects" to align with the Companies Act, 2013. Clause IV was substituted to specify that the liability of members is limited to the amount unpaid on the shares held by them. All references to the Companies Act, 1956 were replaced with corresponding provisions of the Companies Act, 2013.

Thyrocare Technologies has appointed M/s. Price Waterhouse Chartered Accountants LLP as its statutory auditor for a term of five years, effective from the conclusion of the 26th Annual General Meeting (AGM) held on June 30, 2026. The appointment, approved by the company's shareholders, will remain in force until the conclusion of the 31st AGM scheduled for the calendar year 2031. This change follows the completion of the first term of the previous statutory auditor, M/s. M S K A & Associates LLP, at the conclusion of the 26th AGM on June 30, 2026.

The company submitted the intimation to the National Stock Exchange of India Limited and BSE Limited under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was made pursuant to a previous intimation dated May 07, 2026, and based on the Scrutiniser's Report from the AGM.

M/s. Price Waterhouse Chartered Accountants LLP holds ICAI Firm Registration No. 012754N/N500016. The firm was established in 1991 and converted into a limited liability partnership in 2014. Its registered office is located at Sucheta Bhawan, 11A Vishnu Digambar Marg, New Delhi - 110 002, and it operates 17 branch offices across various cities in India.

The firm is a member of Price Waterhouse & Affiliates, a network of distinct and independent Indian Chartered Accountant firms registered with the Institute of Chartered Accountants of India (Network Registration No. NRN/E/14). As of December 31, 2025, the firm employs more than 125 Assurance Partners and holds a valid peer review certificate, auditing various listed companies in India.

Thyrocare Technologies acknowledged the contributions of the outgoing auditor, M/s. M S K A & Associates LLP (ICAI Firm Registration No. 105047W/W101187), and placed on record its appreciation for their services during their tenure. The detailed disclosures required under the SEBI Master Circular No. HO/49/14/14(7)2025-CFDPD2/I/3762/2026 dated January 30, 2026, have been provided in Annexure A to the filing.

Auditor Details